COMMENTARY: Adjuvant vinorelbine plus cisplatin extended survival longer than observation in resected non-small-cell lung cancer

Ellis, Peter M.
March 2007
ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p31
Academic Journal
The article comments on a research study focusing on the use of adjuvant vinorelbine plus cisplatin in the treatment of resected non-small-cell lung cancer. Commenting on the study questions are being raised that which patients should receive adjuvant chemotherapy. The author views that in the study, the data concerning post-operative radiation therapy are conflicting. The adjuvant chemotherapy has not shown any improvement upon the earlier chemotherapy.


Related Articles

  • Adjuvant vinorelbine plus cisplatin extended survival longer than observation in resected non-small-cell lung cancer.  // ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p31 

    The article cites a research study focusing on the use of adjuvant vinorelbine plus cisplatin in the treatment of resected non-small-cell lung cancer. A randomized controlled trial was conducted to determine whether adjuvant vinorelbine along with cisplatin extends survival of the patients...

  • Role of DNA Repair Gene Polymorphisms in the Efficiency of Platinum-Based Adjuvant Chemotherapy for Non-Small Cell Lung Cancer. Mathiaux, Juliette; Le Morvan, Valérie; Pulido, Marina; Jougon, Jacques; Bégueret, Hugues; Robert, Jacques // Molecular Diagnosis & Therapy;May2011, Vol. 15 Issue 3, p159 

    Background: Cisplatin-based adjuvant treatment of non-small cell lung cancer (NSCLC) has become standard, thanks to the studies that have shown a significant survival advantage. The identification of patients who could benefit from this adjuvant treatment would allow ineffective and toxic...

  • TRENDS.  // American Journal of Hematology/Oncology;Oct2009, Vol. 8 Issue 10, p468 

    The article presents abstracts on lung cancer treatments which include the updated survival analysis of study JBR.10 to establish cisplatin-based adjuvant chemotherapy as treatment for early-stage non-small cell lung cancer (NSCLC), maintenance pemetrexed plus supportive care against placebo...

  • Should Platinum-Based Chemotherapy Drugs Be the Gold Standard?  // Pulmonary Reviews;Oct2008, Vol. 13 Issue 10, p12 

    The article discusses research being done on platinum versus non-platinum chemotherapy regimens for small cell lung cancer. It references a study by Isuru Amarasena et al, published in the 2008 issue of "Cochrane Database Systematic Reviews." The study reveals that there is no significant...

  • Response: Re: Anti-Angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. LEE, SIOW MING; HACKSHAW, ALLAN // JNCI: Journal of the National Cancer Institute;12/2/2009, Vol. 101 Issue 23, p1657 

    The article highlights anti-angiogenic therapy, which is a combination of thalidomide and chemotherapy, to treat small cell lung cancer. The authors say that there might have been a higher number of patients with increased thromboembolic events if all patients underwent Doppler ultrasonography...

  • New molecular targeted therapies for advanced non-small-cell lung cancer. Méndez, Míriam; Custodio, Ana; Provencio, Mariano // Journal of Thoracic Disease;Mar2011, Vol. 3 Issue 1, p30 

    Non-small-cell lung cancer (NSCLC) is a uniformly fatal disease and most patients will present with advanced stage. Treatment outcomes remain unsatisfactory, with low long-term survival rates. Standard treatment, such as palliative chemotherapy and radiotherapy, offers a median survival not...

  • Do we have markers to select patients for adjuvant therapies of non-small-cell lung cancer? Konopa, K. // Annals of Oncology;Oct2010 Supplement 7, Vol. 21 Issue suppl_7, pvii199 

    Adjuvant platinum-based chemotherapy represents the standard of care in fit stage II and IIIA non-small-cell lung cancer patients after surgical resection. This review discusses current knowledge on molecular prognostic and predictive tumor features for benefit from adjuvant therapies with...

  • Modern Management of Small-Cell Lung Cancer. Ferraldeschi, Roberta; Baka, Sofia; Jyoti, Babita; Faivre-Finn, Corinne; Thatcher, Nick; Lorigan, Paul // Drugs;2007, Vol. 67 Issue 15, p2135 

    In this article, we review best standard practice for the management of smallcell lung cancer (SCLC) and indicate the likely areas of development over the next 5–10 years. A number of prognostic scores have been developed and these allow more rational decisions on treatment. Treatment...

  • Sequential treatment with ursolic acid chlorophenyl triazole followed by 5-fluorouracil shows synergistic activity in small cell lung cancer cells. Rui-Xia Zhu; Lei Zhao; Yu-Kun Zhang; Peng Luo; Si-Hai Liu; Jin-Guang Wang // Bangladesh Journal of Pharmacology;2015, Vol. 10 Issue 1, p197 

    Combination therapy has prolonged the survival of patients with small cell lung cancer (SCLC), an aggressive neoplasm characterized by a high rate of metastasis. In the present study the effect of sequential treatment of ursolic acid chlorophenyl triazole (UACT) followed by 5-fluorouracil (5-FU)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics